BlackRock Fund Advisors recently announced the acquisition of new stake in Translate Bio Inc. (NASDAQ:TBIO). The institutional investor has increased its shareholding in the Healthcare company by 28.17% to 3.82 million shares with purchase of 0.84 million shares. This fresh investment now brings its stake to 5.14% valued currently at $57.97 million. In addition, RTW Investments LP raised its holdings by 24570.0 to 3.72 million shares. And Federated Global Investment Manag.. has lifted its position by 16.11% or 0.37 million shares – to 2.66 million shares.
With over 1.17 million Translate Bio Inc. (TBIO) shares trading Friday and a closing price of $13.87 on the day, the dollar volume was approximately $16.19 million. The shares have shown a negative weekly performance of -10.89% and its price on 08/28/20 lost nearly -1.56%. Currently, there are 62.28M common shares owned by the public and among those 47.20M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for TBIO have a consensus price objective of $31.57. The analysts have set the share’s price value over the next 12 months at a high of $40.00 and a low of $25.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Translate Bio Inc. stock is 1.50 for the next 12 months. But an upside of 65.33% will see the stock hit the forecast high price target while mean target price for the stock is $30.00.
Insiders at the company have transacted a total of 7 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 500,000 shares. Insider sales of the common stock occurred on 6 occasions, with total insider shares sold totaling 7,078,945 shares.
The top 3 mutual fund holders in Translate Bio Inc. are Fidelity Growth Company Fund, Federated Hermes Kaufmann Small C, and Fidelity Select Port. – Biotechno. Fidelity Growth Company Fund owns 2.88 million shares of the company’s stock, all valued at over $43.7 million. The company sold 72056.0 shares recently to bring their total holdings to about 3.88% of the shares outstanding. Federated Hermes Kaufmann Small C sold -0.11 million shares to see its total holdings shrink to 1.63 million shares valued at over $24.77 million and representing 2.20% of the shares outstanding. Fidelity Select Port. – Biotechno sold -0.14 million shares to bring its total holdings to over 1.38 million shares at a value of $21.03 million. Fidelity Select Port. – Biotechno now owns shares totaling to 1.87% of the shares outstanding.
Shares of Translate Bio Inc. (NASDAQ: TBIO) opened at $14.01, down -$0.08 from a prior closing price of $14.09. However, the script later closed the day at $13.87, down -1.56%. The company’s stock has a 5-day price change of -10.89% and -29.74% over the past three months. TBIO shares are trading 70.39% year to date (YTD), with the 12-month market performance up to 50.11% higher. It has a 12-month low price of $6.80 and touched a high of $28.09 over the same period. Currently, 1.17 million shares have been traded, compared to an average intraday trading volume of 1.96 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.75%, -19.03%, and 13.21% respectively.
Institutional ownership of Translate Bio Inc. (NASDAQ: TBIO) shares accounts for 89.90% of the company’s 62.28M shares outstanding. Mutual fund holders own 51.53%, while other institutional holders and individual stakeholders account for 57.65% and 24.04% respectively.
It has a market capitalization of $1.05B. The earnings-per-share (ttm) stands at -$1.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.10% over the week and 5.46% over the month.
Analysts forecast that Translate Bio Inc. (TBIO) will achieve an EPS of $0.28 for the current quarter, -$0.32 for the next quarter and -$0.68 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.57 while analysts give the company a high EPS estimate of $3.84. Comparatively, EPS for the current quarter was -$0.41 a year ago. Earnings per share for the fiscal year are expected to decrease by -1.70%, and 13.90% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Translate Bio Inc. (TBIO) as a “Strong Buy” at a consensus score of 1.50. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 0 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TBIO, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on July 07, 2020, with the firm’s price target at $18-$32. William Blair coverage for the Translate Bio Inc. (TBIO) stock in a research note released on July 06, 2020 offered a Outperform rating with a price target of. SunTrust was of a view on June 26, 2020 that the stock is Buy, while Jefferies gave the stock Buy rating on July 22, 2019, issuing a price target of $20. ROTH Capital on their part issued Buy rating on June 18, 2019.